Cosmo Pharmaceuticals N.V.

Cosmo confirms full redemption in cash of €175m Convertible Bonds

Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)

Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries

Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa

Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions

Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma

Cosmo presents strong H1 2023 operational and financial results

Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023

Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia

Cosmo announces Cortiment® approval in Japan

Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea

Cosmo Pharmaceuticals announces approval of Winlevi® in Canada

Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting

Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings

Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance

Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™

Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023

Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance

Cosmo and Hyphens Announce Signing of License and Supply Agreements for Winlevi® in Southeast Asia

Cosmo announces successful Phase III clinical trial of Lumeblue™ in China

Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis

GI Genius™ named to FORTUNE 2022 “Change the World” list

Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening

Cosmo and InfectoPharm Announce Signing of License and Distribution Agreement for Winlevi® in Germany, Italy and Austria

Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance

Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China

Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia

Invitation to Cosmo’s Half-Year 2022 Results Webcast on 28 July 2022

Cosmo announces acceptance of NDA submission of Cortiment® MMX® in Japan

Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA